The study analysed that the Synovialsarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females. Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.
Many technologies such as REOLYSIN
technology, ZVex and GLAAS technology, Laser Micro-beam Microdissection are
being developed that can bring the innovative treatment, which can control the
progression of Synovial sarcoma. ZVex and GLAAS are complementary
discovery platforms designed to activate and expand the immune system’s natural
ability to create tumour-specific cytotoxic T cells (CTLs) in vivo.
Download Sample of This Research
Report: https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis/report-sample
The combination of novel drugs against
different organs as well as combination of drugs with biological and
biochemical agents may further enhance the treatment quality.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=synovial-sarcoma-therapeutics-pipeline-analysis
The research also found that various
companies have collaborated for the development of Synovial sarcoma pipeline.
In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc. (Merck) agreed
to explore the therapeutic potential of Merck’s investigational anti-PD-1
therapy, MK-3475, in combination with two of the Pfizer’s oncology assets.
Some of the key players developing
drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc.,
Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.
Synovial sarcoma Pipeline Analysis
·
By Phase
·
By Route of
Administration
·
By Molecule Type
·
By Company
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886
(USA/Canada)
Email: enquiry@psmarketresearch.com
Synovial Sarcoma Exhibits Emerging Pipeline with 22 Drug Candidates
The study analysed that the Synovial sarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect...
No comments:
Post a Comment